| Nov 20 |
Q3 2024 Earnings: Hold Akebia Therapeutics
|
| Nov 14 |
Vadadustat Alternative Dosing Study Results Published in the American Journal of Kidney Disease
|
| Nov 12 |
Akebia Therapeutics to Present at the Jefferies London Healthcare Conference
|
| Nov 9 |
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$5.50
|
| Nov 8 |
Akebia Therapeutics Inc (AKBA) Q3 2024 Earnings Call Highlights: Navigating Revenue Challenges ...
|
| Nov 7 |
Akebia Therapeutics, Inc. (AKBA) Q3 2024 Earnings Call Transcript
|
| Nov 7 |
Akebia Therapeutics (AKBA) Reports Q3 Loss, Misses Revenue Estimates
|
| Nov 7 |
Akebia Therapeutics: Q3 Earnings Snapshot
|
| Nov 7 |
Akebia GAAP EPS of -$0.10, revenue of $37.4M
|
| Nov 7 |
Akebia Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
|
